Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor–induced thrombocytopenia
Mark Bishton(Nottingham University Hospitals NHS Trust), Ricky W. Johnstone(Peter MacCallum Cancer Centre), H. Miles Prince(Peter MacCallum Cancer Centre), Benjamin Martin(Advanced Cancer Therapeutics), Nicole M. McLaughlin(Advanced Cancer Therapeutics), Katya J. Henley(Walter and Eliza Hall Institute of Medical Research), Emma C. Josefsson(Sahlgrenska University Hospital), Chloé James(Université de Bordeaux), Simon J. Harrison(Peter MacCallum Cancer Centre), Benjamin T. Kile(Garvan Institute of Medical Research)
Cited by 134
Related Papers
New and emerging HDAC inhibitors for cancer treatment
|Journal of Clinical Investigation|2014|1.4k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation
|Proceedings of the National Academy of Sciences|1999|632